Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.

Uddin MJ, Crews BC, Xu S, Ghebreselasie K, Daniel CK, Kingsley PJ, Banerjee S, Marnett LJ.

ACS Chem Biol. 2016 Nov 18;11(11):3052-3060. Epub 2016 Sep 19.

2.

Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice.

Santander S, Cebrián C, Esquivias P, Conde B, Esteva F, Jiménez P, Ortego J, Lanas A, Piazuelo E.

Int J Oncol. 2012 Feb;40(2):527-34. doi: 10.3892/ijo.2011.1219. Epub 2011 Oct 3.

PMID:
21971589
3.

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.

Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC, et al.

Br J Pharmacol. 1997 May;121(1):105-17.

4.

Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.

Rathore A, Rahman MU, Siddiqui AA, Ali A, Shaharyar M.

Arch Pharm (Weinheim). 2014 Dec;347(12):923-35. doi: 10.1002/ardp.201400219. Epub 2014 Oct 9.

PMID:
25303727
5.

Indomethacin based new triazolothiadiazine derivatives: Synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies.

Sever B, Altıntop MD, Kuş G, Özkurt M, Özdemir A, Kaplancıklı ZA.

Eur J Med Chem. 2016 May 4;113:179-86. doi: 10.1016/j.ejmech.2016.02.036. Epub 2016 Feb 16.

PMID:
26927686
6.

Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.

Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ.

Cancer Prev Res (Phila). 2011 Oct;4(10):1536-45. doi: 10.1158/1940-6207.CAPR-11-0120. Epub 2011 Sep 7.

7.

In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.

Qin J, Yuan J, Li L, Liu H, Qin R, Qin W, Chen B, Wang H, Wu K.

Biomed Pharmacother. 2009 Mar;63(3):241-8. doi: 10.1016/j.biopha.2008.04.007. Epub 2008 May 23.

PMID:
18617357
8.
9.

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2003 Apr;9(4):1566-72.

10.

Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells.

Berg J, Fellier H, Christoph T, Kremminger P, Hartmann M, Blaschke H, Rovensky F, Towart R, Stimmeder D.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):363-72.

PMID:
10763850
11.

Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents.

Uddin MJ, Crews BC, Ghebreselasie K, Marnett LJ.

Bioconjug Chem. 2013 Apr 17;24(4):712-23. doi: 10.1021/bc300693w. Epub 2013 Mar 28.

12.

Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.

Kalgutkar AS, Kozak KR, Crews BC, Hochgesang GP Jr, Marnett LJ.

J Med Chem. 1998 Nov 19;41(24):4800-18.

PMID:
9822550
13.

Discovery of new indomethacin-based analogs with potentially selective cyclooxygenase-2 inhibition and observed diminishing to PGE2 activities.

Kassab SE, Khedr MA, Ali HI, Abdalla MM.

Eur J Med Chem. 2017 Dec 1;141:306-321. doi: 10.1016/j.ejmech.2017.09.056. Epub 2017 Sep 28.

PMID:
29031075
14.

A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.

Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, Thaiparambil J, Coward L, Gorman G, Li Y, Sani B, Hobrath JV, Maxuitenko YY, Reynolds RC.

Cancer Prev Res (Phila). 2009 Jun;2(6):572-80. doi: 10.1158/1940-6207.CAPR-09-0001. Epub 2009 May 26.

15.

Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors.

Lu X, Zhang H, Li X, Chen G, Li QS, Luo Y, Ruan BF, Chen XW, Zhu HL.

Bioorg Med Chem. 2011 Nov 15;19(22):6827-32. doi: 10.1016/j.bmc.2011.09.034. Epub 2011 Sep 25.

PMID:
22000948
16.

Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.

Ninomiya I, Nagai N, Oyama K, Hayashi H, Tajima H, Kitagawa H, Fushida S, Fujimura T, Ohta T.

Oncol Rep. 2012 Sep;28(3):777-84. doi: 10.3892/or.2012.1885. Epub 2012 Jun 26.

17.

[Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].

Réti A.

Magy Onkol. 2010 Dec;54(4):377-81. doi: 10.1556/MOnkol.54.2010.4.12. Hungarian.

18.

Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site.

Xu S, Uddin MJ, Banerjee S, Duggan K, Musee J, Kiefer JR, Ghebreselasie K, Rouzer CA, Marnett LJ.

J Biol Chem. 2019 May 31;294(22):8690-8698. doi: 10.1074/jbc.RA119.007405. Epub 2019 Apr 18.

19.

Inhibition of cell survival, cell cycle progression, tumor growth and cyclooxygenase-2 activity in MDA-MB-231 breast cancer cells by camphorataimide B.

Lin WL, Lee YJ, Wang SM, Huang PY, Tseng TH.

Eur J Pharmacol. 2012 Apr 5;680(1-3):8-15. doi: 10.1016/j.ejphar.2012.01.032. Epub 2012 Feb 10.

PMID:
22329896
20.

Novel Thiourea Derivatives Bearing Sulfonamide Moiety as Anticancer Agents Through COX-2 Inhibition.

Ghorab MM, El-Gaby MSA, Alsaid MS, Elshaier YAMM, Soliman AM, El-Senduny FF, Badria FA, Sherif AYA.

Anticancer Agents Med Chem. 2017;17(10):1411-1425. doi: 10.2174/1871520617666170327153735.

PMID:
28356021

Supplemental Content

Support Center